OPKO Health Applauds the President’s Bold Plan to Transform Kidney Care
Miami, July 15, 2019 —On July 10th, President Trump announced a bold vision for transforming kidney care for the estimated 37 million Americans affected by chronic kidney disease (CKD). The President laid out the Administration’s detailed plan to increase earlier detection and care of CKD and to increase incentives to develop new and cutting-edge treatments for patients.
“The OPKO Renal Division applauds the President and his Administration, Secretary Azar and the broader community focused on kidney care, for taking meaningful steps to improve the wellbeing of CKD patients. We are supporting these steps by educating patients and healthcare professionals about CKD and one of its main complications, secondary hyperparathyroidism (SHPT), promoting prompt diagnosis and treatment, and developing and increasing access to alternative treatment options for this complication,” said Charlie Bishop, PhD, CEO, OPKO Renal Division, Miami, FL.
About OPKO Renal Division:
The Renal Division of OPKO Health, Inc. is developing proprietary products to treat secondary hyperparathyroidism associated with CKD and vitamin D insufficiency. These products are designed to treat patients with stage 3, 4 or 5 CKD, but they also have potential application to other indications including metabolic bone disease, such as renal osteodystrophy and osteoporosis.